Biomaterial Database

[The quantities of main urinary metabolite of PGF, plasma PGF and plasma PGE in pulmonary diseases]. 1982

W Takahashi

Radioimmunoassays of urinary 5 alpha-7 alpha-dihydroxyketotetranorprosta-1,16-dioic acid and its delta-lactone(main urinary metabolite of PGF, PGF-MUM) were performed for the patients with several pulmonary diseases. The quantities of PGE and PGF in plasma for the patients with pulmonary emphysema especially were also measured by radioimmunoassay. Following results were obtained. 1) Twenty-four hours secretions of PGF-MUM in normal subjects were 18.4 +/- 9.1 microgram/day (24.5 +/- 9.2 microgram/day in male, 12.2 +/- 2.6 microgram/day in female) on an average. The values of PGF-MUM in male were significantly higher than those in female (P less than 0.03). 2) Twenty-four hours secretions of PGF-MUM for the patients with pulmonary emphysema were significantly lower (P less than 0.01) than those in the normal controls (P less than 0.01), and the values of PGF-MUM were correlated significantly (r=0.451, P less than 0.05) with arterial oxygen partial pressure. 3) Twenty-four hours secretions of PGF-MUM in the patients with asthma bronchiale, chronic bronchitis, hypersensitivity pneumonitis, pulmonary fibrosis and lung cancer were not significantly different from those in the normal controls. But, higher values of PGF-MUM were contained in the pulmonary fibrosis group, and the values of PGF-MUM were correlated with the serum LDH levels (r= 0.652, P less than 0.01). 4) The plasma PGF quantities were 0.7 +/- 0.5 ng/ml and the plasma PGE quantities were 1.7 +/- 0.6 ng/ml in normal subjects on an average. 5) The plasma PGF and PGE quantities in the patients with pulmonary emphysema were not significantly different from those in the normal controls. 6) A significant inverse correlation was observed between the decrease changes of pulmonary arterial pressures and the changes of plasma PGE quantities after oxygen inhalation for the patients with pulmonary emphysema (r= -0.737, P 0.01).

UI	MeSH Term	Description	Entries
D008171	Lung Diseases	Pathological processes involving any part of the LUNG.	Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D008175	Lung Neoplasms	Tumors or cancer of the LUNG.	Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010102	Oxygen Inhalation Therapy	Inhalation of oxygen aimed at restoring toward normal any pathophysiologic alterations of gas exchange in the cardiopulmonary system, as by the use of a respirator, nasal catheter, tent, chamber, or mask. (From Dorland, 27th ed & Stedman, 25th ed)	Inhalation Therapy, Oxygen,Therapy, Oxygen Inhalation,Inhalation Therapies, Oxygen,Oxygen Inhalation Therapies,Therapies, Oxygen Inhalation
D011458	Prostaglandins E	(11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities.	PGE
D011460	Prostaglandins F	(9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics.	PGF
D011656	Pulmonary Emphysema	Enlargement of air spaces distal to the TERMINAL BRONCHIOLES where gas-exchange normally takes place. This is usually due to destruction of the alveolar wall. Pulmonary emphysema can be classified by the location and distribution of the lesions.	Emphysema, Pulmonary,Centriacinar Emphysema,Centrilobular Emphysema,Emphysemas, Pulmonary,Focal Emphysema,Panacinar Emphysema,Panlobular Emphysema,Pulmonary Emphysemas,Centriacinar Emphysemas,Centrilobular Emphysemas,Emphysema, Centriacinar,Emphysema, Centrilobular,Emphysema, Focal,Emphysema, Panacinar,Emphysema, Panlobular,Emphysemas, Centriacinar,Emphysemas, Centrilobular,Emphysemas, Focal,Emphysemas, Panacinar,Emphysemas, Panlobular,Focal Emphysemas,Panacinar Emphysemas,Panlobular Emphysemas
D011658	Pulmonary Fibrosis	A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D001991	Bronchitis	Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	Bronchitides